Tumor- and circulating-free DNA methylation identifies clinically relevant small cell lung cancer subtypes

Abstract

Small cell lung cancer (SCLC) is an aggressive malignancy composed of distinct transcriptional subtypes, but implementing subtyping in the clinic has remained challenging, particularly due to limited tissue availability. Given the known epigenetic regulation of critical SCLC transcriptional programs, we hypothesized that subtype-specific patterns of DNA methylation could be detected in tumor or blood from SCLC patients. Using genomic-wide reduced-representation bisulfite sequencing (RRBS) in two cohorts totaling 179 SCLC patients and using machine learning approaches, we report a highly accurate DNA methylation-based classifier (SCLC-DMC) that can distinguish SCLC subtypes. We further adjust the classifier for circulating-free DNA (cfDNA) to subtype SCLC from plasma. Using the cfDNA classifier (cfDMC), we demonstrate that SCLC phenotypes can evolve during disease progression, highlighting the need for longitudinal tracking of SCLC during clinical treatment. These data establish that tumor and cfDNA methylation can be used to identify SCLC subtypes and might guide precision SCLC therapy.

Shown for reading. Its publisher allows quoting it, not republishing it.

References 77

1. 1.

   Horn L, Mansfield AS, Szczesna A, Havel L, Krzakowski M, Hochmair MJ, Huemer F, Losonczy G, Johnson ML, Nishio M, et al. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. N Engl J Med. 2018;379:2220-2229.

   Not in our library10.1056/nejmoa1809064 (opens in a new tab)

2. 2.

   Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Ozguroglu M, Ji JH, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394:1929-1939.

   Not in our library10.1016/s0140-6736(19)32222-6 (opens in a new tab)

3. 3.

   Byers LA, Chiappori A, Smit M-AD. Phase 1 study of AMG 119, a chimeric antigen receptor (CAR) T cell therapy targeting DLL3, in patients with relapsed/refractory small cell lung cancer (SCLC). J Clin Oncol. 2019;37:1–TPS8576.

   Not in our library10.1200/jco.2019.37.15_suppl.tps8576 (opens in a new tab)

4. 4.

   Hipp S, Voynov V, Drobits-Handl B, Giragossian C, Trapani F, Nixon AE, Scheer JM, Adam PJ. A Bispecific DLL3/CD3 IgG-Like T-Cell Engaging Antibody Induces Antitumor Responses in Small Cell Lung Cancer. Clin Cancer Res. 2020;26:5258-5268.

   Not in our library10.1158/1078-0432.ccr-20-0926 (opens in a new tab)

5. 5.

   Paz-Ares L, Champiat S, Lai WV, Izumi H, Govindan R, Boyer M, Hummel HD, Borghaei H, Johnson ML, Steeghs N, et al. Tarlatamab, a First-In-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small Cell Lung Cancer: An Open-Label, Phase I Study. J Clin Oncol. 2023;JCO2202823.

   Not in our library10.1200/jco.22.02823 (opens in a new tab)

6. 6.

   Pietanza MC, Waqar SN, Krug LM, Dowlati A, Hann CL, Chiappori A, Owonikoko TK, Woo KM, Cardnell RJ, Fujimoto J, et al. Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer. J Clin Oncol. 2018;36:2386-2394.

   Not in our library10.1200/jco.2018.77.7672 (opens in a new tab)

7. 7.

   Howlader N, Forjaz G, Mooradian MJ, Meza R, Kong CY, Cronin KA, Mariotto AB, Lowy DR, Feuer EJ. The Effect of Advances in Lung-Cancer Treatment on Population Mortality. N Engl J Med. 2020;383:640-649.

   Not in our library10.1056/nejmoa1916623 (opens in a new tab)

8. 8.

   Rudin CM, Poirier JT, Byers LA, Dive C, Dowlati A, George J, Heymach JV, Johnson JE, Lehman JM, MacPherson D, et al. Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. Nat Rev Cancer. 2019;19:289-297.

   Not in our library10.1038/s41568-019-0133-9 (opens in a new tab)

9. 9.

   Baine MK, Hsieh MS, Lai WV, Egger JV, Jungbluth AA, Daneshbod Y, Beras A, Spencer R, Lopardo J, Bodd F, et al. SCLC Subtypes Defined by ASCL1, NEUROD1, POU2F3, and YAP1: A Comprehensive Immunohistochemical and Histopathologic Characterization. J Thorac Oncol. 2020;15:1823-1835.

   Not in our library10.1016/j.jtho.2020.09.009 (opens in a new tab)

10. 10.

    Gay CM, Stewart CA, Park EM, Diao L, Groves SM, Heeke S, Nabet BY, Fujimoto J, Solis LM, Lu W, et al. Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell. 2021;39:346-360.

    Not in our library10.1016/j.ccell.2020.12.014 (opens in a new tab)

11. 11.
    Recurrent WNT pathway alterations are frequent in relapsed small cell lung cancer · 2018

    No notice
12. 12.

    Xie M, Chugh P, Broadhurst H, Lai Z, Whitston D, Paz-Ares L, Gay C, Byers L, Rudin CM, Stewart R, et al. Abstract CT024: Durvalumab (D) + platinum-etoposide (EP) in 1L extensive-stage small-cell lung cancer (ES-SCLC): Exploratory analysis of SCLC molecular subtypes in CASPIAN. Cancer Research. 2022;82:CT024.

    Not in our library10.1158/1538-7445.am2022-ct024 (opens in a new tab)

13. 13.
    Molecular profiles of small cell lung cancer subtypes: Therapeutic implications · 2021

    No notice
14. 14.

    Chen H, Gesumaria L, Park Y-K, Oliver TG, Singer DS, Ge K, Schrump DS. BET Inhibitors Target the SCLC-N Subtype of Small-Cell Lung Cancer by Blocking NEUROD1 Transactivation. Molecular Cancer Research. 2023;21:91-101.

    Not in our library10.1158/1541-7786.mcr-22-0594 (opens in a new tab)

15. 15.

    Small Cell Lung Cancer (2022). 2021.

    Not in our library

16. 16.

    Blackhall F, Frese KK, Simpson K, Kilgour E, Brady G, Dive C. Will liquid biopsies improve outcomes for patients with small-cell lung cancer? The Lancet Oncology. 2018;19:e470-e481.

    Not in our library10.1016/s1470-2045(18)30455-8 (opens in a new tab)

17. 17.

    Church M, Carter L, Blackhall F. Liquid Biopsy in Small Cell Lung Cancer—A Route to Improved Clinical Care? Cells. 2020;9.

    Not in our library10.3390/cells9122586 (opens in a new tab)

18. 18.

    Sivapalan L, Iams WT, Belcaid Z, Scott SC, Niknafs N, Balan A, White JR, Kopparapu P, Cann C, Landon BV, et al. Dynamics of Sequence and Structural Cell-Free DNA Landscapes in Small-Cell Lung Cancer. Clin Cancer Res. 2023;29:2310-2323.

    Not in our library10.1158/1078-0432.ccr-22-2242 (opens in a new tab)

19. 19.

    Drapkin BJ, George J, Christensen CL, Mino-Kenudson M, Dries R, Sundaresan T, Phat S, Myers DT, Zhong J, Igo P, et al. Genomic and Functional Fidelity of Small Cell Lung Cancer Patient-Derived Xenografts. Cancer Discovery. 2018;8:600-615.

    Not in our library10.1158/2159-8290.cd-17-0935 (opens in a new tab)

20. 20.

    Stewart CA, Gay CM, Xi Y, Sivajothi S, Sivakamasundari V, Fujimoto J, Bolisetty M, Hartsfield PM, Balasubramaniyan V, Chalishazar MD, et al. Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer. Nat Cancer. 2020;1:423-436.

    Not in our library10.1038/s43018-019-0020-z (opens in a new tab)

21. 21.
    cfDNA methylome profiling for detection and subtyping of small cell lung cancers · 2022

    No notice
22. 22.

    Fialkoff G, Takahashi N, Sharkia I, Gutin J, Pongor L, Rajan A, Nichols S, Sciuto L, Vilimas R, Graham C, et al. Subtyping of Small Cell Lung Cancer using plasma cell-free nucleosomes. bioRxiv. 2022.

    Not in our library10.1101/2022.06.24.497386 (opens in a new tab)

23. 23.

    Esfahani MS, Hamilton EG, Mehrmohamadi M, Nabet BY, Alig SK, King DA, Steen CB, Macaulay CW, Schultz A, Nesselbush MC, et al. Inferring gene expression from cell-free DNA fragmentation profiles. Nature Biotechnology. 2022;40:585-597.

    Not in our library10.1038/s41587-022-01222-4 (opens in a new tab)

24. 24.

    Gaga M, Chorostowska-Wynimko J, Horvath I, Tammemagi MC, Shitrit D, Eisenberg VH, Liang H, Stav D, Levy Faber D, Jansen M, et al. Validation of Lung EpiCheck, a novel methylation-based blood assay, for the detection of lung cancer in European and Chinese high-risk individuals. Eur Respir J. 2021;57.

    Not in our library10.1183/13993003.02682-2020 (opens in a new tab)

25. 25.

    George J, Lim JS, Jang SJ, Cun Y, Ozretic L, Kong G, Leenders F, Lu X, Fernandez-Cuesta L, Bosco G, et al. Comprehensive genomic profiles of small cell lung cancer. Nature. 2015;524:47-53.

    Not in our library10.1038/nature14664 (opens in a new tab)

26. 26.

    Yoshihara K, Shahmoradgoli M, Martínez E, Vegesna R, Kim H, Torres-Garcia W, Treviño V, Shen H, Laird PW, Levine DA, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nature Communications. 2013;4.

    Not in our library10.1038/ncomms3612 (opens in a new tab)

27. 27.

    Chen B, Khodadoust MS, Liu CL, Newman AM, Alizadeh AA. Profiling Tumor Infiltrating Immune Cells with CIBERSORT. Cancer Systems Biology. 2018;243-259.

    Not in our library10.1007/978-1-4939-7493-1_12 (opens in a new tab)

28. 28.

    Cadieux EL, Mensah NE, Castignani C, Tanić M, Wilson GA, Dietzen M, Dhami P, Vaikkinen H, Verfaillie A, Martin CC, et al. Copy number-aware deconvolution of tumor-normal DNA methylation profiles. BioRxiv. 2022.

    Not in our library10.1101/2020.11.03.366252 (opens in a new tab)

29. 29.
    SCLC-CellMiner: A Resource for Small Cell Lung Cancer Cell Line Genomics and Pharmacology Based on Genomic Signatures · 2020

    Not checked
30. 30.
    A Landscape of Pharmacogenomic Interactions in Cancer · 2016

    No notice
31. 31.

    Weirich S, Khella MS, Jeltsch A. Structure, Activity and Function of the Suv39h1 and Suv39h2 Protein Lysine Methyltransferases. Life. 2021;11.

    Not in our library10.3390/life11070703 (opens in a new tab)

32. 32.

    Fuks F. The DNA methyltransferases associate with HP1 and the SUV39H1 histone methyltransferase. Nucleic Acids Research. 2003;31:2305-2312.

    Not in our library10.1093/nar/gkg332 (opens in a new tab)

33. 33.

    Hu X, Estecio MR, Chen R, Reuben A, Wang L, Fujimoto J, Carrot-Zhang J, McGranahan N, Ying L, Fukuoka J, et al. Evolution of DNA methylome from precancerous lesions to invasive lung adenocarcinomas. Nature Communications. 2021;12:687.

    Not in our library10.1038/s41467-021-20907-z (opens in a new tab)

34. 34.

    Van Paemel R, De Koker A, Caggiano C, Morlion A, Mestdagh P, De Wilde B, Vandesompele J, De Preter K. Genome-wide study of the effect of blood collection tubes on the cell-free DNA methylome. Epigenetics. 2021;16:797-807.

    Not in our library10.1080/15592294.2020.1827714 (opens in a new tab)

35. 35.
    Single-cell transcriptomic profiling reveals the tumor heterogeneity of small-cell lung cancer · 2022

    No notice
36. 36.
    ASCL1 and NEUROD1 Reveal Heterogeneity in Pulmonary Neuroendocrine Tumors and Regulate Distinct Genetic Programs · 2016

    Not checked
37. 37.

    Polley E, Kunkel M, Evans D, Silvers T, Delosh R, Laudeman J, Ogle C, Reinhart R, Selby M, Connelly J, et al. Small Cell Lung Cancer Screen of Oncology Drugs, Investigational Agents, and Gene and microRNA Expression. J Natl Cancer Inst. 2016;108.

    Not in our library10.1093/jnci/djw122 (opens in a new tab)

38. 38.

    Tang M, Abbas HA, Negrao MV, Ramineni M, Hu X, Hubert SM, Fujimoto J, Reuben A, Varghese S, Zhang J, et al. The histologic phenotype of lung cancers is associated with transcriptomic features rather than genomic characteristics. Nat Commun. 2021;12:7081.

    Not in our library10.1038/s41467-021-27341-1 (opens in a new tab)

39. 39.

    Zaitsev A, Chelushkin M, Dyikanov D, Cheremushkin I, Shpak B, Nomie K, Zyrin V, Nuzhdina E, Lozinsky Y, Zotova A, et al. Precise reconstruction of the TME using bulk RNA-seq and a machine learning algorithm trained on artificial transcriptomes. Cancer Cell. 2022;40:879-894.

    Not in our library10.1016/j.ccell.2022.07.006 (opens in a new tab)

40. 40.

    Sato Y, Okamoto I, Kameyama H, Kudoh S, Saito H, Sanada M, Kudo N, Wakimoto J, Fujino K, Ikematsu Y, et al. Integrated Immunohistochemical Study on Small-Cell Carcinoma of the Lung Focusing on Transcription and Co-Transcription Factors. Diagnostics (Basel). 2020;10.

    Not in our library10.3390/diagnostics10110949 (opens in a new tab)

Questions about this paper

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.